Last reviewed · How we verify
Dipropylin (ALVERINE)
Dipropylin (generic name: ALVERINE) is a alverine drug. It is currently in Phase 2 development.
Alverine works by relaxing the muscles in the digestive tract to reduce spasms and cramping.
Dipropylin, also known as Alverine, is a small molecule drug in the alverine class. Its exact target is unknown, but it is used to treat gastrointestinal spasms and irritable bowel syndrome. The commercial status of Alverine is unclear, but it is likely available as a generic medication. Key safety considerations include potential gastrointestinal side effects. Alverine's mechanism of action is not well understood, but it is thought to work by relaxing smooth muscle in the gastrointestinal tract.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ALVERINE |
|---|---|
| Drug class | alverine |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
Imagine your digestive tract as a long tube with muscles that help move food through it. When these muscles get too active, it can cause painful spasms and cramping. Alverine helps calm these muscles, making it easier to digest food and reducing discomfort.
Approved indications
Common side effects
Key clinical trials
- Ebastine Versus Mebeverine in IBS Patients (PHASE3)
- Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders (PHASE3)
- Enteric-Coated Peppermint Oil Versus Standard Antispasmodic in SLC6A4 (5-HTTLPR) Carriers With Irritable Bowel Syndrome. (NA)
- The Instant Efficacy and Safety of Alverine in Decreasing Portal Hypertension: an Exploratory Pilot Study (PHASE2)
- Carvedilol and Alverine in Portal Hypertension (PHASE2,PHASE3)
- The Safety and Efficacy of Alverine in the Treatment of Cirrhotic Portal Hypertension (PHASE2,PHASE3)
- The Efficacy and Safety of Alverine in the Treatment of Portal Hypertension in Patients With Liver Cirrhosis (PHASE2,PHASE3)
- To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dipropylin CI brief — competitive landscape report
- Dipropylin updates RSS · CI watch RSS
Frequently asked questions about Dipropylin
What is Dipropylin?
How does Dipropylin work?
What is the generic name of Dipropylin?
What drug class is Dipropylin in?
What development phase is Dipropylin in?
Related
- Drug class: All alverine drugs
- Therapeutic area: All drugs in Pain
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing